Britain and America have hammered out a landmark trade agreement that will keep zero tariffs on British drug products entering the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has pledged to raise funding on drugs through the public health system. This move ensures that import taxes on these vital products will remain at nothing for a duration of three years.
This deal comes after earlier statements to hike import taxes on branded pharmaceutical imports, with figures floated up to double the cost.
"This agreement with the Britain bolsters the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British medicine commerce," a statement declared.
Trade Importance
Pharmaceuticals are one of the UK's largest export categories to the US, which is clearly the biggest destination for large British pharmaceutical firms.
Statistics show that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products worth £11.1bn to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This agreement secures work, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for medical research," a government official stated.
Key UK Commitments
The pact includes several notable commitments from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new therapies to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a aim to double total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Industry Background
The pact follows a protracted row between the sector and the British authorities over medicine costs and approval rates.
The disagreement were intensified by claims that US customers were paying several times more for the same drugs than consumers in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been directed toward US facilities.
The Science Minister stated that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
